NASH predicts plasma inflammatory biomarkers independently of visceral fat in men

Obesity

Volumn 16, Issue 6, 2008, Pages 1394-1399

  Targher, Giovanni ^a,b   Bertolini, Lorenzo ^a   Rodella, Stefano ^a   Lippi, Giuseppe ^b   Franchini, Massimo ^c   Zoppini, Giacomo ^b   Muggeo, Michele ^b   Day, Christopher P ^d  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c Civil Hospital   (Italy)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; FATTY LIVER; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MALE; METABOLISM; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; RISK FACTOR; STATISTICAL MODEL;

ADIPONECTIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FATTY LIVER; FIBRINOGEN; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LINEAR MODELS; MALE; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TRIGLYCERIDES;

EID: 44449109670     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.64     Document Type: Article

References (43)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.
2. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
3. Lyon CJ, Law RE, Hsueh WA. Mini-review: adiposity, inflammation, and atherogenesis. Endocrinology 2003;144:2195-2200.
4. Kannel WB. Overview of haemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005;40:1215-1220.
5. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005;3:1879-1883.
6. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923.
7. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22:1129-1133.
8. Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med 2006;6:19-25.
9. Targher G, Bertolini L, Scala L et al. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 2005;22:1354-1358.
10. Haukeland JW, Damas JK, Konopski Z et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006;44:1167-1174.
11. Yoneda M, Mawatari H, Fujita K et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007;42:573-582.
12. Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. J Hepatol 2006;45:879-881.
13. Targher G, Bertolini L, Scala L et al. Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. Diabetes Care 2007;30:e31-e32.
14. Nguyen-Duy TB, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab 2003;284:E1065-E1071.
15. Adiels M, Taskinen MR, Packard C et al. Overproduction of large VLDL particles is driven by increased liver fat content in men. Diabetologia 2006;49:755-765.
16. Kolak M, Westerbacka J, Velagabudi VR et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007;56:1960-1968.
17. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
18. Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
19. Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-750.
20. Armellini F, Zamboni M, Robbi R et al. Total and intra-abdominal fat measurements by ultrasound and computerized tomography. Int J Obes Relat Metab Disord 1993;17:209-214.
21. Ribeiro-Filho FF, Faria AN, Azjen S, Zanella MT, Ferreira SRG. Methods of estimation of visceral fat: advantages of ultrasonography. Obes Res 2003;11;1488-1494.
22. Targher G, Tonoli M, Agostino G et al. Ultrasonographic intra-abdominal depth and its relation to haemostatic factors in healthy males. Int J Obes Relat Metab Disord 1996;20:882-885.
23. Jakobsen MU, Berentzen T, Sorensen TIA, Overvad K. Abdominal obesity and fatty liver. Epidemiol Rev 2007;29:77-87.
24. Day CP. From fat to inflammation. Gastroenterology 2006;130:207-210.
25. Targher G, Bertolini L, Rodella S et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (oxf) 2006;64:679-683.
26. Targher G, Bertolini L, Padovani R et al. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men. Role of visceral fat accumulation. Diabetes Care 2004;27:2498-1500.
27. Brea A, Mosquera D, Martin E et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis. A case-control study. Arterioscler Thromb Vasc Biol 2005;25:1045-1500.
28. Targher G, Bertolini L, Padovani R et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006;29:1325-1330.
29. Targher G, Bertolini L, Padovani R et al. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007;46:1126-1132.
30. Villanova N, Moscatiello S, Ramilli S et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42:473-478.
31. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121.
32. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
33. Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873.
34. Targher G, Bertolini L, Padovani R et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30:1212-1218.
35. Targher G, Bertolini L, Poli F et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54:3541-3546.
36. Hamaguchi M, Kojima T, Takeda N et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579-1584.
37. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007;191:235-240.
38. Alessi MC, Bastelica D, Mavri A et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003;23:1262-1268.
39. Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 2007;46:716-722.
40. Targher G, Bertolini L, Scala L et al. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (oxf) 2004;61:700-703.
41. Bugianesi E, Pagotto U, Manini R et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005;90: 3498-3504.
42. Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.
43. Xu A, Wang Y, Keshaw H et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.